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Abstract 
 
Histone modifications are important for maintaining the transcription program. BET proteins, 
an LPSRUWDQWFODVVRI³KLVWRQHUHDGLQJSURWHLQs´ have recently been described as essential in 
bone biology. This study presents the therapeutic opportunity of BET protein inhibition in 
osteoporosis. We find that the pharmacological BET protein inhibitor JQ1 rescues pathologic 
bone loss in a post-ovariectomy osteoporosis model by increasing the trabecular bone volume 
and restoring mechanical properties. The BET protein inhibition suppresses osteoclast 
differentiation and activity as well as the osteoblastogenesis in vitro. Moreover, we show that 
treated non-resorbing osteoclasts could still activate osteoblast differentiation. In addition, 
specific inhibition of BRD4 using RNA interference inhibits osteoclast differentiation but 
strongly activates osteoblast mineralization activity. Mechanistically, JQ1 inhibits expression 
of the master osteoclast transcription factor NFATc1 and the transcription factor of osteoblast 
Runx2. These findings strongly support that targeting epigenetic chromatin regulators such as 
BET proteins may offer a promising alternative for the treatment of bone-related disorders 
such as osteoporosis. 
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1. Introduction 
Bone is a dynamic tissue in constant change through a physiological remodeling 
process involving bone-specific cells; the osteoclasts which are responsible for the resorption 
of old or damaged bone and the osteoblasts which are specialized in the formation of a new 
bone [1, 2]. In physiological conditions the balance between bone resorption and bone 
formation is required to maintain constant bone mass for the majority of adulthood. 
Disruption of this physiological balance leads to the development of bone-related disorders. 
Osteoporosis is the most prevalent bone disease in older women and men, characterized by a 
low bone mass, reduced bone mineral density, and deterioration of bone microarchitecture 
leading to an increased fracture risk. In osteoporosis the rate of bone resorption exceeds the 
rate of bone formation, thus decreasing the bone mass [1]. Currently, most available agents in 
clinical use to treat osteoporosis inhibit bone resorption, whereas only a few stimulate bone 
formation and restore bone mass [3]. 
Recent molecular and genetic studies, identifying numerous local and systemic 
regulators of bone resorption, have considerably improved our molecular knowledge of bone 
remodeling [4]. Amongst them, epigenetic regulation which include posttranslational histone 
modifications, miRNA-mediated post-transcriptional regulation and DNA methylation play an 
important role in bone biology [5, 6]. 
Bromodomain and extra-terminal domain (BET) protein family (BRD2, BRD3, 
BRD4, and BRDT), through its ability to bind to acetylated lysine on histone tails, is an 
LPSRUWDQW FODVV RI ³KLVWRQH UHDGLQJ SURWHLQ´ [7]. Bromodomains act as a scaffold for 
molecular complexes at the recognized histone sites in order to regulate chromatin 
accessibility to transcription factors and RNA polymerase [8]. Recently, several BET protein 
inhibitors have been developed including JQ1 and I-BET151. They were described as a new 
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therapeutic approach in various preclinical cancer models [9-13]. In addition, these small-
molecule inhibitors of BET proteins were recently identified to suppress bone destruction in 
many distinct inflammatory diseases (arthritis, periodontitis, bone tumour, osteoporosis) [11, 
14-16]. 
In this study, we confirm the therapeutic potential of BET protein inhibition, by using 
JQ1, to reverse bone loss induced by estrogen deficiency. Morever, our findings deepthly 
demonstrate that JQ1 rescues bone mass and bone strength in ovariectomy-induced 
osteoporotic mice by interfering with osteoblast and osteoclast differentiation. We observed 
that JQ1 treated-osteoclasts could still activate osteoblastogenesis in vitro. Importantly, we 
provide evidence that BET protein inhibition does not affect the structure and mechanical 
properties of bone in physiological conditions. These findings reinforce the therapeutic 
potential of BET protein inhibition in diseases characterized by an impairment of bone 
formation. 
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2. Materials and Methods 
2.1 Therapeutic agents 
The BRD4 inhibitor, JQ1, was kindly provided by James Bradner (Dana-Farber Cancer 
Institute) and used for in vitro and in vivo studies. This synthetic compound selectively targets 
the acetyl-lysine binding pocket of BET proteins. For the in vitro studies, JQ1 was dissolved 
in dimethyl sulfoxide (DMSO) at 10mM stock solution and stored at -20°C. For the in vivo 
studies, JQ1 was dissolved in DMSO at 50mg/ml, and then diluted in 10% hydroxypropyl 
beta cyclodextrin (HP-ȕ-CD, Sigma Aldrich) to obtain the final concentration, 50 mg/kg, and 
stored at 4oC. The 10% HP-ȕ-CD was prepared in sterile water, which was filtered with 0.22 
micron filter. 
2.2 Animal Treatment 
All procedures involving mice [their housing in the Experimental Therapeutic Unit at the 
Faculty of Medicine of Nantes (France) and care, the method by which they were anesthetized 
and killed, and all experimental protocols] were all conducted in accordance with the 
LQVWLWXWLRQDO JXLGHOLQHV DQG ZHUH DSSURYHG E\ WKH ³(WKLF &RPPLWWHH IRU $QLPDO
([SHULPHQWDWLRQ´ &(($3G/ /LFHQFH   8-week old C57BL/6 female mice 
ovariectomized (OVX) or SHAM-operated (SHAM) from Janvier Labs (Le Genest-Saint-Isle, 
France), were left untreated for 2 weeks, and then treated with JQ1 (50 mg/kg) or vehicle 
(n=6 for each group), twice a day by intraperitoneal (I.P.) injection. In a second experiment, 
6-week old C57BL/6 male mice (Janvier labs) were treated with JQ1 (50 mg/kg) or vehicle 
twice a day by I.P. injection (n=6 for each group). For dynamic bone histomorphometry, mice 
were injected (I.P.) with calcein (20 mg/kg) at 7 days and 2 days before sacrifice. At sacrifice, 
the femurs, tibiae and vertebrae L4 were collected for further analysis. 
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2.3 Micro Computed Tomography (microCT) Analysis. 
Micro computed tomography (microCT) analysis was performed as previously described [3]. 
Briefly, tibias were scanned using high-resolution microcomputed tomography (Skyscan 
.RQWLFK%HOJLXPDWN9DQGȝ$XVLQJDPPDOXPLQLXPILOWHUDQd a detection 
pixel size of 9µm. Images were captured every 0.7° through 180° rotation, and analysed using 
Skyscan software. Trabecular structures positioned 0.2 mm below the growth plate, were 
quantified over a length of 1mm. Cortical bone positioned 1 mm below the growth plate, was 
quantified over a length of 1mm. For the lumbar vertebra L4, the central 60% of the 
trabecular bone was analysed. Bone volume/total volume fraction (BV/TV), trabecular 
thickness (Tb.Th.), trabecular separation (Tb.Sp.), trabecular number (Tb.N.) and Cortical 
thickness (Ct. Th) were determined. 
2.4 Bone Histomorphometric Analysis 
Tibias were decalcified with 4.13% DTA and 0.2% paraformaldehyde in phosphate buffered 
saline (PBS) for 96 hours using the KOS microwave histostation (Milestone, Kalamazoo, MI) 
EHIRUHHPEHGGLQJ LQSDUDIILQ6HFWLRQVȝPWKLFN/HLFD0LFURV\VWHPVZHUHDQDO\]HGE\
tartrate-resistant acid phosphatase (TRAP) staining as described previously[17, 18]. 
Immunostaining for Osterix was performed as described [17] with a rabbit anti-osterix 
antibody (1/25; Abcam, Cambridge, MA, http://www.abcam.com). Quantification of 
osteoclast number (TRAP+ cells) and osteoblast number (osterix+ cells) in the metaphyseal 
spongiosa was evaluated manually using ImageJ software.in 0.4 mm2 region of interest (ROI). 
For undecalcified histology, tibias were methylmethacrylate-embedded for microtome 
VHFWLRQLQJȝPIRUYRQ.RVVDVWDLQLQJ 
For the dynamic histomorphometry, tibia were dissected and embedded in 
methylmethacrylate as previously described [3]. Thin sections were mounted unstained and 
analysed using an image analysis software program (Qwin) interfaced with a microscopy 
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using a DMRXA epifluorescent microscope (Leica). All comparisons of staining intensities 
were made at 200x magnifications. 
2.5 Three Point Bending 
Bones were subjected to three point bending analysis using a Bose Electroforce 3200 
mechanical testing machine with a 450 N load cell. Rounded supports and press head were 
used with a constant span support distance of 6 mm for all femurs. Bones were positioned 
horizontally with the press head contacting the midshaft. A preload of 0.25 N was applied to 
the bone before compressing at a constant force of 0.25 N/sec until failure. From the force-
displacement curve, stiffness (N/mm) was calculated from the linear region and maximum 
load from the peak force.  
2.6 Osteoclast Differentiation 
Generation of osteoclasts from human CD14+ monocytes was described previously [19]. 
Briefly, purified CD14+ cells fURPGLIIHUHQWGRQRUVZHUHFXOWXUHGLQĮ-MEM with 10% FCS 
and 25 ng/ml human M-CSF (R&D systems). After 4 days of culture, 100ng/ml RANKL was 
added. Multinucleated cells formed with 3 nuclei and more were counted after TRAP staining 
(Sigma, France). The resorption capacity was assessed on 96-well Corning Osteo Assay ®. 
Mature osteoclasts were cultured with 25 ng/mL hMCSF, 100 ng/mL RANKL and JQ1 at 
various concentrations. After 3 days of culture, cells were removed with bleach solution and 
resorption pits area was quantified using Image J software (NIH, Bethesda, MD). 
2.7 Osteoblast Differentiation 
Before passage 5, human MSCs were seeded at 104 cells per centimeter square in 96-well 
plates in DMEM supplemented with vitamin D3 (10í M; Hoffmann-La Roche, Basel, 
Switzerland), dexamethasone (10í M; Sigma) and with or without JQ1 as indicated (this 
represented day 0 for MSC osteogenic differentiation). Three days later, freshly prepared 
ascorbic acid (50 ȝg/ml; Sigma) and ȕ-glycerophosphate (10 mM; Sigma) was added to allow 
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mineralization, this medium being changed every 2±3 days. Alizarin red-S staining was used 
to detect the mineralized nodules formed in vitro as described previously [20]. Briefly, 
between day 19 and 21, cells were fixed in ice-cold 70% ethanol for 1 hour and incubated 
with Alizarin red-S (40mM, pH 7.4; Sigma) for 10 minutes at room temperature. After 
extensive washing, images were captured using a stereo microscope (Stemi 2000-C; Zeiss, 
Oberkochen, Germany), and mineralized surfaces were quantified using the Qwin software 
(Leica, Nussloch, Germany). 
2.8 Quantitative Reverse Transcription-PCR 
Total RNA was extracted from cultured cells using TRIreagent (Invitrogen Life 
Technologies). Total RNA was reversed transcribed using the ThermoScript RT-PCR System 
(Life Technologies). Real-time monitoring of PCR amplification of complementary DNA 
(cDNA) was performed using DNA primers (primers sequences are available upon request) 
on CFX96 real-time PCR detector system (Bio-Rad, Marnes la Coquette, France) with SYBR 
PCR Master Mix buffer (Bio-Rad). Target gene expression was normalized to GAPDH levels 
in respective samples as an internal standard, and the comparative cycle threshold (Ct) 
method was used to calculated relative quantification of target mRNAs. Primers for each gene 
are described in Supplemental Information. Each assay was performed in triplicate. 
2.9 Gene silencing 
Knock-down of BRD2, BRD3, and BRD4 using short hairpin RNA (shRNA) in human pre-
OCs and human MSCs cells were obtained by lentiviral cell transduction as described 
previously [21]. They were used for lentivirus production following the protocols provided 
with the ViraPower Lentiviral Expression System (Invitrogen). A multiplicity of infection of 
10 was used to transduce MSCs cells and of 4 was used to transduce pre-OCs cells. shRNA 
targeting LacZ was used as a control. 
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2.9 Statistical Analysis 
Data were tested for normality using a Kolmogorov-Smirnov test. The mean ± SEM was 
calculated for all groups and compared by two-tailed paired Students t test or by ANOVA, 
ZLWKWKH'XQQHWW¶VPXOWLSOHFRPSDULVRQVWHVWIRUpost-hoc analysis. p < 0.05 was used as the 
criteria for statistical significance.  
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3. Results 
3.1 BET protein inhibition rescues osteoporosis in ovariectomized mice 
We first examined whether a BET protein inhibitor, JQ1, could increase bone mass in 
ovariectomized mice with established bone loss. We left SHAM-operated or ovariectomized 
(OVX) 8-week-old mice without treatment for 2 weeks to notice a significant bone loss, then 
treated them with vehicle or JQ1 (50 mg/kg twice per day) for 4 weeks (Figure 1A). Von 
Kossa stained cross sections and micro-computed tomography (ȝCT) analysis of the 
metaphyseal region of the proximal tibia confirmed the expected trabecular bone loss caused 
by ovariectomy (34% of trabecular bone volume decrease compared with SHAM, P < 0.001) 
before treatment (Figure 1A and figure 1B). After 4 weeks of JQ1 treatment, trabecular bone 
volume was higher than in OVX mice treated with vehicle (125%, P < 0.001) and SHAM-
operated controls (68%, P < 0.01; Figure 1B). The increase in trabecular bone volume was 
associated with greater trabecular number and trabecular thickness (respectively +106%, P < 
0.001 and +9%, P < 0.05) and lower trabecular separation (-34%, P < 0.001; figure 1B). 
Three-point bending of the left femoral diaphysis was performed to test bone strength. 
Ovariectomy without treatment resulted in lower stiffness (-14.3%, P < 0.05, Figure 1C) and 
maximum load (-5.4%) compared to SHAM-operated control mice. JQ1 treatment of OVX 
mice resulted in greater bone strength, with a higher stiffness (17.7%, P < 0.05, Figure 1C) 
and maximum load (8.3%) compared to OVX-vehicle mice. Histomorphometric analysis of 
trabecular bone in the proximal tibia at the end of the experiment, showed a decrease in 
osteoclast and osteoblast number in OVX animals treated with vehicle (Oc.N./ROI and 
Ob.N/ROI ; Figure 1D) while a treatment with BET protein inhibitor significantly increased 
osteoclast and osteoblast number suggesting a greater bone remodeling. Similarly to tibiae, 
trabecular bone mass in the lumbar vertebra L4 was significantly greater in OVX-JQ1 treated 
mice compared to OVX mice treated with the vehicle after 7 days of treatment (Figures 1E 
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and 1F). These results demonstrate that JQ1 treatment strongly reverses an established 
osteopenia induced by ovariectomy. 
 
3.2 BET protein inhibition blocks osteoclast differentiation and activity 
To understand the mechanisms responsible for the correction of osteopenia in OVX mice, we 
examined the effects of BET protein inhibition on OB and OC differentiation. The mRNA 
expression levels of the different BET proteins were quantified along with osteoclast 
differentiation. This revealed a late decrease of BRD2, BRD3 and BRD4 expression associated 
to an increase of the master transcription factor of osteoclastogenesis NFATc1 (Nuclear factor 
of activated T-cells cytoplasmic 1 under the activation of NF-kB pathway [22]) at day 7 
(Figure 2A), suggesting that BET proteins are required in the first steps of osteoclast 
formation. To evaluate the importance of the BET proteins during osteoclast differentiation 
we first assessed the effect of JQ1 on osteoclast differentiation. JQ1 significantly inhibited 
osteoclastogenesis in a dose dependent manner without affecting survival, as revealed by OC 
precursor viability measured by Crystal Violet staining (Figure 2B). Moreover, JQ1 treatment 
significantly reduced the osteoclastic bone resorption in vitro (43% decrease of resorbed 
surface at 250nM, figure 2C). This inhibition of osteoclast formation and activity came with a 
strong reduction of tartrate-resistant acid phosphatase (TRAP, 80%) and cathepsinK (Ctsk, 
87%) expression, two markers of OC differentiation and activity (Figure 2D). 
To identify the underlying mechanism of JQ1-mediated inhibition of OC differentiation, we 
then tested the activity of NF-kB using a luciferase-based reporter construct containing its 
consensus-binding site. Cells expressing RANK were transfected with the NF-kB promoter 
construct and were then treated with RANKL RU71)Į in the presence or absence of JQ1. Our 
results showed that the inhibition of BET proteins by JQ1 treatment reduced RANKL- and 
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TNFĮ-stimulated NF-kB transcriptional activity (respectively more than 30% and 40%, 
supplementary figure S1). These findings are sustained by the decrease of NF-kB target genes 
NFATc1 and MMP9 mRNA expression (respectively 92% and 34%, figure 2D) in JQ1-treated 
OC precursors. Our findings demonstrate that inhibition of BET proteins disrupt both OC 
formation and activity. 
3.3 Specific inhibition of BRD2, BRD3 and BRD4 recapitulate JQ1 inhibition of 
osteoclast differentiation in vitro 
To make sure the inhibition of the BET proteins was the key mechanism behind the observed 
effect of JQ1 on osteoclastogenesis, we transduced pre OCs (CD14+ cells) with a combination 
of shBRD2, shBRD3 and shBRD4 (shBRDs). The knock-down of BRD2, BRD3, and BRD4 
were validated at mRNA levels 2 days after transduction (Figure 3A). The efficiency of three 
different shRNA for the BRDs was previously validated on human mesenchymal stem cells 
(hMSCs) (Supplementary Figure S2). 
Transduced pre OCs were then cultured with RANKL to induce their differentiation. After 7 
days of culture in differentiation medium, shBRDs-transduced cells did not differentiate into 
OCs while pre-OCs transduced with shLacZ were still able to differentiate into OCs. It is 
associated with a reduction of relative expression of hNFATc1 and hMMP9 (respectively 90% 
and 66%, figure 3B). This confirmed that the simultaneous inhibition of the three BRDs 
recapitulates the effects of JQ1 on osteoclastogenesis.  
Pre OCs were then transduced with shRNAs specific for BRD2 or BRD3 or BRD4. In these 
conditions, we observed the same effects that we previously described with a combination of 
three shBRDs. The silencing of BRD2, BRD3 or BRD4 led to a decrease in osteoclast 
formation (respectively 95%, 90% and 92%) and to an inhibition of NFATc1 and MMP9 
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expression levels (Figure 3C), confirming the critical role of each BRDs in 
osteoclastogenesis. 
3.4 BET protein inhibition decreases osteoblast differentiation in vitro 
The effects of BET protein inhibition on osteoblastic differentiation have been tested using 
JQ1 inhibitor. Human MSCs from different donors were cultured for 21 days in the presence 
of OB differentiation medium. The expression levels of the different BET proteins were 
evaluated throughout OB differentiation in vitro and revealed a concomitant late increase of 
BRD2, BRD3 and BRD4 parallel to the late stage marker of osteoblastogenesis alkaline 
phosphatase (ALP), at days 14 and 21 (Figure 4A). 
In order to evaluate the importance of the BET proteins during OB differentiation, we set up 
two different experiments. First, hMSCs were cultured for 21 days in presence of OB 
differentiation medium and JQ1 continuously for 21 days. Alizarin red Staining was 
performed at the end of the culture to assess mineralization and therefore OB differentiation 
(Figure 4B). JQ1 treatment (125nM) resulted in a marked decrease of mineralization without 
any effect on cell proliferation/survival as revealed by cell viability assessed by Crystal Violet 
staining (Figure 4B). We then examined the expression of a critical transcription factor for 
OB differentiation, RUNX2, and a late stage marker of osteoblastogenesis, ALP. In both cases, 
JQ1 treatment led to a significant decrease of their gene expression (Figure 4B). 
Second, to evaluate when the expression of the BET proteins is the most critical to OB 
differentiation, the same experiments were repeated with a JQ1 treatment only applied during 
the last 7 days of the differentiation protocol. Similar effects to the first experiment were 
observed in terms of inhibition of mineralization and RUNX2 and ALP expression (Figure 
4C). As suggested by Figure 4A, the BET proteins expression in the last steps of the OB 
differentiation is of utmost importance. 
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Considering the resulting increase in bone mass in OVX-mice treated with JQ1 and the direct 
effects of JQ1 observed on osteoblasts and osteoclasts, we next asked whether JQ1 could 
interfere into the osteoclast-osteoblast crosstalks and promotote bone formation. We 
investigated in vitro the activity of preosteoclasts (pre OCs) and osteoclasts (OCs) treated 
with JQ1 on the differentiation of mesenchymal stem cells into osteoblasts. We revealed that 
in both case, JQ1 did not modify the ability of pre OCs and OCs to activate osteoblastogenesis 
as suggested by the expression of hRunx2 (Figure 4D and supplementary figure S3).  
 
3.5 Inhibition of BRD2, BRD3 and BRD4 recapitulates JQ1 inhibition of osteoblast 
differentiation in vitro 
To confirm that BET proteins are involved in osteoblast differentiation, human MSCs were 
cultured in OB differentiation medium and transduced with a combination of shBRD2, 
shBRD3, shBRD4 (shBRDs). After 3 days, expression of BRD2, BRD3, and BRD4 RNA was 
assessed by qRT-PCR to validate the efficiency of the shRNAs (Figure 5A). After 21 days of 
culture, mineralization quantification by alizarin red staining and quantification of RUNX2 
expression revealed a significant inhibition of OB differentiation by shBRDs compared to 
shLacZ and confirmed that the simultaneous inhibition of the three BRDs recapitulates the 
effects of JQ1 on OB differentiation (Figure 5B). 
Similarly to the experiments performed on osteoclasts, we asked the question whether BRD2, 
BRD3 and BRD4 are individually essential for osteoblastogenesis. hMSCs were transduced 
with shRNAs specific for BRD2, BRD3 or BRD4. Interestingly, silencing of BRD2 or BRD3 
reduced the extent of OB differentiation as suggested by a reduction of the mineralized area 
and hRUNX2 expression, whereas the transduction of hMSCs with shBRD4 had the opposite 
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effect (Figure 5C). Indeed, BRD4 knockdown increased the osteoblastic differentiatiation as 
revealed by a greater mineralized surface and a stable expression of hRUNX2 (Figure 5C). 
 
3.6 BET protein inhibition slightly increases normal bone mass without affecting its 
mechanical properties 
We tested whether BET protein inhibition could affect the normal bone architecture. Healthy 
6 week old mice (C57BL6) were treated for 28 days using JQ1 at 50mg/kg. Von Kossa 
stained cross sections and ȝCT images of the metaphyseal region of the tibia revealed an 
increase in trabecular bone mass (Figure 6A). JQ1 treatment induced a significant increase in 
trabecular bone volume (BV/TV, 44%, P<0.01), associated with an increase in trabecular 
number (Tb.N.) and trabecular thickness (Tb.Th.) (respectively, 18% P<0.01 and 22% 
P<0.001 ; figure 6B). A significant increase in cortical bone thickness in the presence of JQ1 
was also observed (13.2 %, P<0.05; figure 6B). The biomechanical properties of the femurs 
were assessed by three point bending. No changes were observed in terms of bone stiffness 
and maximum load (Figure 6C) in the presence of JQ1 treatment, meaning the JQ1 treated 
bone was as strong as the vehicle treated bone. Similar results were observed for the analysis 
of lumbar vertebra L4 (Figure 6D-E). 
3.7 BET protein inhibition decreases osteoclast number in vivo 
Histomorphometric analysis of trabecular bone in the proximal tibia showed a significant 
decrease in osteoclast number in JQ1 treated animals (Oc.N.; Figure 7A). The number of 
TRAP-positive OCs lining the bone surface revealed that JQ1 induced an early decrease in 
osteoclast numbers as early as 3 days after the beginning of treatment which continued to 
reduce to day 28 (Figure 7A). Oc.N was significantly decreased at day 7 (37%, p<0.05) 
compared to vehicle-treated mice. The same serial histological sections were used for Osterix 
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staining revealing the number of osteoblasts lining on bone surface. No significant difference 
of OB number per millimeter could be observed in presence of JQ1 whatever the time of 
treatment (Figure 7B). During the experiment, two injections of fluorescent calcein were 
performed 7 days and 2 days prior to sacrifice at day 14. On the basis of fluorescence images 
of the trabecular bone from the tibiae of vehicle or JQ1 treated mice (Figure 7C), we 
concluded that JQ1 did not significantly affect the mineral apposition rate (MAR (µm/day)) 
and bone formation (BFR/BS (µm2/µm3/day)) in physiological conditions. 
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Discussion  
According to the world health organization, osteoporosis affects more than 75 million 
people in the United States, Europe and Japan and the lifetime risk of fracture has been 
estimated to be between 30 and 40% in developed countries. The treatment of this disease is 
considered essential to the maintenance of health and quality of life because of its morbid 
consequences. 
Emerging evidences suggest that epigenetic modulations play an important role in 
bone biology and may offer new targets to treat bone diseases [5, 23, 24]. Thus, BET proteins 
are a group of epigenetic regulators that bind to acetylated lysine on histone tails to regulate 
chromatin accessibility to transcription factors and RNA polymerase [7, 8]. Numerous small-
molecule were developed to target BET proteins in pre-clinical models of cancers especially 
in hematological malignancies [9, 10, 12, 25-28]. Currently, some BET protein inhibitors are 
being tested in early phase clinical trials illustrating the therapeutic potential of this new class 
of drugs (clinicaltrials.gov references NCT02157636, NCT02259114, NCT02158858 and 
NCT02308761). In this context, we recently showed that, JQ1, one of the BET protein 
inhibitor was able to suppress osteosarcoma mediated bone remodeling in a preclinical model 
[11]. Since then, several studies have shown that BET protein inhibition seems to be a 
potential candidate for the treatment of bone related diseases associated with inflammation 
[14-16]. 
Here we report data to support and confirm that BET protein inhibition could be a 
promising treatment for osteoporosis. We directly challenged an existing ovariectomy-
induced osteopenia and rescued it using JQ1. This preclinical study demonstrates the potential 
of JQ1 as curative treatment in ovariectomized mice with established bone loss, leading to a 
greater trabecular bone volume (both in long bones and vertebra) associated with a greater 
bone strength after only 28 days of treatment. These results corroborate recent studies 
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demonstrating that various BET protein inhibitors could increase bone mass in rheumatoid 
arthritis, periodontitis and osteoporosis preclinical models [14-16]. 
Histomorphometric observations revealed a decrease of osteoclast number in OVX-
mice at the end of experiment which could be explain by a massive reduction of bone 
parameters in cancellous bone after 6 weeks of ovariectomy. Nevertheless, histomorphometry 
revealed an increase of both osteoclast and osteoblast number within the cancellous bone in 
OVX-animal treated with JQ1 compared to vehicle treated animals. This fact may be explain 
by our in vitro observation showing that BET protein inhibition does not prevent pre OCs and 
OCs to initiate osteoblastogenesis, suggesting that JQ1 could have a potential anabolic 
activity. This study over a longer culture period would confirm this observation through 
quantification of mineralization. We hypothesize that JQ1 can dissociate the two osteoclasts 
functions and inhibit its bone resorption activity whilst maintaining its osteoblast 
differentiation activation potential. To demonstrate in vivo that JQ1 has anabolic potential in 
OVX mice, another in vivo experiment might be performed using calcein labeling at different 
time points of the experiment to assess bone formation. This hypothesis is supported by 
Karsdal et al. who report data supporting the possibility of un-coupling bone resorption and 
bone formation, with OCs presenting anabolic factors even if their resorption activity is 
inhibited [29]. Patients suffering from osteopetrosis with mutations in the chloride channel of 
the osteoclast proton pump are excellent examples of this phenomenon. Indeed, those patients 
have reduced bone resorption associated with increased bone formation and not the classical 
secondary decrease in bone formation normally observed with classical anti-resorptive 
molecules [30]. Moreover, those patients present an increased number of non-resorbing OCs 
associated with an increased number of active OBs, exactly as we observed after JQ1 
treatment [31]. 
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In the present study, we confirmed that intraperitoneal injection of JQ1 did not exert 
any adverse effect especially on normal bone [15, 32]. A moderate increased bone mass was 
observed without affecting any bone strength parameters. Histomorphological analysis of 
healthy mice revealed an early decrease in osteoclast numbers without any change in 
osteoblast number explaining the increase of bone mass. Thus, we could consider that BET 
protein inhibition has an effect on bone remodeling only in bone disorders such as in 
osteoporosis.  
Mechanistically, our study confirms that BET protein inhibition induces an inhibition 
of both osteoclast differentiation and activity as well as of osteoblasts in vitro [11, 25]. 
Interestingly, we did observe the same effects after BRD2, BRD3 and BRD4 silencing 
together with shRNAs confirming the central role of the BET proteins in bone cells 
differentiation and activity. However, the specific BRD4 silencing in human mesenchymal 
stem cells results in a greater mineralization which could be mediated by BRD2 and BRD3 in 
substitution for Brd4 and thus regulating genes that are usually activate by BRD4. This 
hypothesis has to be tested by ChIP for BRD2 and BRD3. The specific silencing of BRD2 
and BRD3 caused both disruption of osteoblast and osteoclast differentiation. Thus, 
considering the higher affinity of JQ1 for BRD4, it appears that BRD4 is the key BET protein 
targeted by JQ1 in bone biology, exerting specific activity on bone cells. Emerging evidences 
are considering the activity of BRD4 as a regulator of lineage specific gene associated with 
enhancer elements [33]. Moreover, aging is widely associated with the accumulation of 
molecular defects over time and alteration of the normal epigenetic pattern. In this context, it 
has been suggested that an aging associated disorder such as osteoporosis could have an 
important epigenetic component. [5, 34]. Thus, we could consider that in bone related 
disorders, the activity of BRD4 is modified in bone cells leading to an inhibition of bone 
formation and activation of bone resorption. JQ1, as a specific inhibitor of BRD4, would 
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blocking these mechanisms, and consequently increase bone mass. It is suggested by Park-
Min who showed that BRD4 binds to the promoter of NFATc1, the master transcription factor 
of osteoclastogenesis, which is displaced with I-BET151 and thus decrease of NFATc1 
expression [14]. We did observe similar decrease of NFATc1 expression with JQ1. 
In conclusion, BET protein inhibitors result in a decrease in osteoclast differentiation 
and activity but do not affect their potential to activate osteoblasts. Furthermore, we show that 
blocking BET protein signaling with JQ1 administration can reverse the bone loss that occurs 
with estrogen deficiency through increases in bone mass, structure and strength. This robust 
response suggests that inhibition of BET protein signaling with JQ1 represents a promising 
new therapeutic approach for the treatment of bone-related disorders. 
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Figure legends 
Figure1 : JQ1 rescues osteoporosis in ovariectomized mice. 
(A) Representative longitudinal sections coloured with Von Kossa staining and representative 
transverse microCT images of the proximal tibia metaphysis, taken ex vivo, from SHAM mice 
treated with vehicle or OVX mice treated with vehicle or JQ1 for 28 days (n=6 for each 
group) (B) MicroCT analysis of trabecular bone volume (BV/TV (%)), trabecular number 
(Tb.N (/mm), trabecular thickness (Tb.Th (mm)) and trabecular separation (Tb.Sp (mm)) of 
the tibia of SHAM mice treated with vehicle or OVX mice treated with vehicle or JQ1. (C) 
Three point bending analysis of stiffness and maximum load of the left femur of SHAM mice 
treated with vehicle (open bars) or OVX mice treated with vehicle (hatched bars) or JQ1 
(black bars). (n=4 for each group). (D) Histogram showing osteoclast number (Oc.N./ROI) 
and osteoblast number (Ob.N./ROI) in SHAM mice treated with vehicle (open bars) or OVX 
mice treated with vehicle (hatched bars) or JQ1 (black bars) at the end of experiment (28 
days). (E) Representative longitudinal and transverse microCT images of lumbar vertebra L4, 
taken ex vivo, from SHAM mice treated with vehicle or OVX mice treated with vehicle or 
JQ1 for 7 days. (F) MicroCT analysis of trabecular bone volume (BV/TV (%)), trabecular 
number (Tb.N (/mm)), trabecular thickness (Tb.Th (mm)) and trabecular separation (Tb.Sp 
(mm)) of lumbar vertebra L4 of SHAM mice treated with vehicle (open bars) or OVX mice 
treated with vehicle (hatched bars) or JQ1 (black bars). ROI is a region of interest of 0.4mm2 
Data represent mean r SEM, * p < 0.05, ** p<0.01, *** p<0.001, compared to vehicle by 
ANOVA followed by a post test (Bonferroni). 
 
Figure 2: BET proteins inhibition inhibits osteoclast differentiation 
Purified human CD14+ monocytes were cultured for 7 days in the presence of M-CSF and 
RANKL. (A) mRNA levels of hNFATc1, hBRD2, hBRD3 and hBRD4 were assessed by 
qRT-PCR at different time points of the culture (D4,D5 and D7). Results are expressed as fold 
change compared to the condition without RANKL at day4. (B) Purified human CD14+ 
monocytes were cultured for 7 days in the presence of M-CSF, RANKL and JQ1 at different 
concentrations. TRAP colouration was performed at the end of the culture period (scale bar, 
100 mm) and multinucleated TRAP-positive cells were counted under a light microscope 
(colored bars) and the cell viability was assessed by Crystal Violet (line) (Results are 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
25 
 
expressed as percentage of the control condition without JQ1). (C) Resorption lacunae and 
percentage of resorbed area obtained by osteoclasts (from CD14+) cultured on OsteoAssay 
plate treated with or without JQ1. Digital images were captured using resident image capture, 
NIH ImageJ software was used for image analysis. (D) Purified human CD14+ monocytes 
were cultured for 7 days in the presence of M-CSF, RANKL and JQ1 as indicated. mRNA 
levels of hTRAP, hCtsk, hNFATc1 and hMMP9 were assessed by qRT-PCR at the end of the 
culture period. Data represent mean r SEM, * p < 0.05, ** p<0.01, *** p<0.001, compared to 
vehicle by ANOVA followed by a post test (Bonferroni). 
 
Figure 3: Inhibition of BRD2, BRD3 and BRD4 recapitulate JQ1 inhibition of osteoclast 
differentiation in vitro. 
(A) Human CD14+ cells were transduced with a combination of shBRD2, shBRD3, shBRD4 
(shBRDs). After 48 hours, hBRD2, hBRD3 and hBRD4 RNA levels were assessed by qRT-
PCR. (B) After 7 days, cultured in OC differentiation medium, multinucleated TRAP-positive 
cells were counted under a light microscope (scale bars, 100 mm) and expression of hNFATc1 
and hMMP9 were assessed by qRT-PCR. (C) Human CD14+ cells were transduced with 
shBRD2 or shBRD3 or shBRD4. After 48 hours, expression of hBRD2, hBRD3 and hBRD4 
RNA levels were respectively assessed by qRT-PCR. After 7 days, cultured in OC 
differentiation medium, multinucleated TRAP-positive cells were counted under a light 
microscope and expression of hNFATc1 and hMMP9 were assessed by qRT-PCR. Data 
represent mean r SEM, * p < 0.05, ** p<0.01, *** p < 0.001 compared to vehicle by Student 
t-test. 
 
Figure 4: BET proteins inhibition inhibits osteoblast differentiation. human MSCs  were 
cultured for 21 days in the presence of OB differentiation medium. (A) mRNA levels of 
hALP, hBRD2, hBRD3 and hBRD4 were assessed by qRT-PCR at different time points of the 
culture (D4,D5, D7, D14 and D21). Results are expressed as fold increase compared to the 
condition without diff. medium at day 4. (B) hMSCs were cultured for 21 days in the presence 
of OB differentiation medium and JQ1 for 21 days. Alizarin red staining was performed at the 
end of the culture and mineralization was quantified (each set of bars represents data from 
independant donors) and the cell viability was assessed by Crystal Violet (line). mRNA levels 
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of hRunx2 and hALP were assessed by qRT-PCR. (C) hMSCs were cultured for 21 days in the 
presence of OB differentiation medium and JQ1 for the last seven days of culture period. 
Alizarin red Staining was performed at the end of the culture and mineralization was 
quantified (colored bars) and the cell viability was assessed by Crystal Violet (line). mRNA 
levels of hRunx2 and hALP were assessed by qRT-PCR. (D) Expression of hRunx2 in hMSCs 
co-cultured with vehicle- or JQ1- treated pre OCs or mature OCs. Error bars show s.e.m. for 
n=3 measurement from representative experiments. *p < 0.05; *p < 0.01; ***p < 0.001, 
compared to vehicle by 1-way ANOVA followed by a post test (Bonferroni). 
 
Figure 5 : BET proteins are essential for osteoblast differentiation. 
(A) Human MSCs were cultured in OB differentiation medium and transduced with a 
combination of shBRD2, shBRD3, shBRD4 (shBRDs). After 2 days, expression of hBRD2, 
hBRD3 and hBRD4 RNA levels were assessed by qRT-PCR (B) After 21 days of culture, 
mineralization was quantified after staining with alizarin red-S and expression of hRunx2 was 
assessed by qRT-PCR. (C) Human MSCs were transduced with shBRD2 or shBRD3 or 
shBRD4. After 2 days, expression of hBRD2, hBRD3 and hBRD4 RNA level were 
respectively assessed by qRT-PCR. After 21 days, cultured in OB differentiation medium, 
mineralization was quantified after staining with alizarin red-S and expression of hRunx2 
expression was assessed by qRT-PCR. Data represent mean r SEM, *p < 0.05; *p < 0.01, *** 
p < 0.001 compared to control condition by Student t-test. 
 
 
Figure 6: JQ1 increases normal bone mass without affecting its mechanical properties. 
(A) Representative longitudinal sections coloured with Von Kossa staining and representative 
transverse microCT images of the proximal tibia metaphysis, taken ex vivo, from mice treated 
with JQ1 (50 mg/kg) or vehicle (Veh.) for 28 days. (B) MicroCT analysis of trabecular bone 
volume (BV/TV (%)), trabecular number (Tb.N (/mm), trabecular thickness (Tb.Th (mm)) 
and cortical thickness (Ct.Th (mm)) of the tibia of mice treated with JQ1 (black bars) or 
vehicle (bopen bars) for 28 days (n=6). (C) Three point bending analysis of stiffness and 
maximum load of the left femur of mice treated with vehicle (open bars) or JQ1 (black bars). 
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(n=4 for each group). (D) Representative longitudinal and transverse microCT images of the 
lumbar vertebra L4, taken ex vivo, from mice treated with JQ1 (50 mg/kg) or vehicle (Veh.) 
for 28 days. (E) MicroCT analysis of trabecular bone volume (BV/TV (%)), trabecular 
number (Tb.N (/mm), trabecular thickness (Tb.Th (mm)) and trabecular separation (Tb.Sp 
(mm)) of the lumbar vertebra L4 of mice treated with JQ1 (black bars) or vehicle (open bars) 
for 7 days. Data represent mean r SEM, ** p < 0.01, *** p < 0.001 compared to vehicle by 
Student t-test. 
 
Figure 7: JQ1 induces an early decrease in osteoclast numbers. 
(A) Histological sections of the tibiae of mice treated with vehicle or JQ1 at day 7. Arrow 
identify TRAP-positive osteoclasts lining trabecular bone surfaces. Histogram showing 
osteoclast number (Oc.N./BS (/mm)) in mice treated with vehicle (open bars) or JQ1 (black 
bars) for 3  (n=6), 7 (n=6) and 28 days (n=6). (B) Histological sections of the tibiae of mice 
treated with vehicle or JQ1 at day 7. Arrow identify Osterix-positive osteoblasts lining 
trabecular bone surfaces. Histogram showing osteoblast number (Ob.N./BS (/mm)) in mice 
treated with vehicle (open bars) or JQ1 (black bars) for 3  (n=6), 7 (n=6) and 28 days (n=6). 
(C) Fluorescence images of the tibia of vehicle or JQ1 treated mice. Histograms showing 
mineral apposition rate (MAR (µm/day)) and bone formation (BFR/BS (µm2/µm3/day)) in 
vehicle (open bars) and JQ1 (black bars) treated mice at day 14. Data represent mean r SEM. 
Scale bar 100µm. 
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Highlights 
 BET proteins play a key role in bone cells differentiation and activity 
 JQ1 preserved both mass and quality of bones in osteoporotic mice. 
 JQ1 is an epigenetically active drug and represents a new therapeutic approach of anti-
osteoporotic agents. 
